TherapeuticsMD, Inc. (TXMD)

TherapeuticsMD Statistics

Total Valuation

TherapeuticsMD has a market cap or net worth of $14.47 million. The enterprise value is $14.66 million.

Market Cap	14.47M
Enterprise Value	14.66M

Important Dates

The next estimated earnings date is Wednesday, November 12, 2025, after market close.

Earnings Date	Nov 12, 2025
Ex-Dividend Date	n/a

Share Statistics

TherapeuticsMD has 11.57 million shares outstanding. The number of shares has increased by 2.98% in one year.

Current Share Class	11.57M
Shares Outstanding	11.57M
Shares Change (YoY)	+2.98%
Shares Change (QoQ)	+0.19%
Owned by Insiders (%)	1.61%
Owned by Institutions (%)	12.35%
Float	9.56M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.91
Forward PS	n/a
PB Ratio	0.56
P/TBV Ratio	0.61
P/FCF Ratio	16.87
P/OCF Ratio	16.87
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	5.73
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	17.51

Financial Position

The company has a current ratio of 2.89, with a Debt / Equity ratio of 0.24.

Current Ratio	2.89
Quick Ratio	2.10
Debt / Equity	0.24
Debt / EBITDA	n/a
Debt / FCF	7.89
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -1.98% and return on invested capital (ROIC) is -4.11%.

Return on Equity (ROE)	-1.98%
Return on Assets (ROA)	-3.61%
Return on Invested Capital (ROIC)	-4.11%
Return on Capital Employed (ROCE)	-6.72%
Revenue Per Employee	$2.56M
Profits Per Employee	-$459,000
Employee Count	1
Asset Turnover	0.07
Inventory Turnover	n/a

Taxes

Income Tax	-63,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.38% in the last 52 weeks. The beta is 0.57, so TherapeuticsMD's price volatility has been lower than the market average.

Beta (5Y)	0.57
52-Week Price Change	-21.38%
50-Day Moving Average	1.11
200-Day Moving Average	1.11
Relative Strength Index (RSI)	60.86
Average Volume (20 Days)	506,808

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TherapeuticsMD had revenue of $2.56 million and -$459,000 in losses. Loss per share was -$0.04.

Revenue	2.56M
Gross Profit	2.56M
Operating Income	-2.27M
Pretax Income	-607,000
Net Income	-459,000
EBITDA	-1.89M
EBIT	-2.27M
Loss Per Share	-$0.04

Balance Sheet

The company has $6.07 million in cash and $6.60 million in debt, giving a net cash position of -$535,000 or -$0.05 per share.

Cash & Cash Equivalents	6.07M
Total Debt	6.60M
Net Cash	-535,000
Net Cash Per Share	-$0.05
Equity (Book Value)	27.29M
Book Value Per Share	2.36
Working Capital	8.80M

Cash Flow

Operating Cash Flow	837,000
Capital Expenditures	n/a
Free Cash Flow	837,000
FCF Per Share	$0.07

Margins

Gross margin is 100.00%, with operating and profit margins of -88.82% and -17.94%.

Gross Margin	100.00%
Operating Margin	-88.82%
Pretax Margin	-23.72%
Profit Margin	-17.94%
EBITDA Margin	-73.70%
EBIT Margin	-88.82%
FCF Margin	32.71%

Dividends & Yields

TherapeuticsMD does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.98%
Shareholder Yield	-2.98%
Earnings Yield	-3.25%
FCF Yield	5.93%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 9, 2022. It was a reverse split with a ratio of 1:50.

Last Split Date	May 9, 2022
Split Type	Reverse
Split Ratio	1:50

Scores

TherapeuticsMD has an Altman Z-Score of -33.64 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-33.64
Piotroski F-Score	4